CAR-T

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Endpoints
Bristol-Myers Squibb
drug manufacturing
cell therapy
liso-cel
CAR-T
Flag link:
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
BioSpace
Bristol-Myers Squibb
CAR-T
Orva-Cel
Flag link:
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Fierce Pharma
FDA
Bristol-Myers Squibb
liso-cel
CAR-T
Flag link:
New study points to why CAR-T therapy may fail in some lymphoma patients
New study points to why CAR-T therapy may fail in some lymphoma patients
Fierce Biotech
CAR-T
lymphoma
Flag link:
Janssen flags accelerated approval milestone in Europe for CAR-T therapy
Janssen flags accelerated approval milestone in Europe for CAR-T therapy
Biopharma Reporter
JNJ
Janssen
CAR-T
EMA
Europe
cilta-cel
Flag link:
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Flag link:
Bold Predictions for Medtech in 2021
Bold Predictions for Medtech in 2021
Medical Devices and Diagnostics Industry
devices
Medtech
COVID-19
remote patient monitoring
telemedicine
home care
digital medicine
artificial intelligence
machine learning
robotic surgery
3D printing
Joe Biden
gene editing
microbiome
CAR-T
Flag link:
Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years
Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years
Endpoints
Factor Bioscience
cell therapy
MRNA
CAR-T
Flag link:
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Endpoints
Autolus Therapeutics
ESMO
CAR-T
diffuse large B-cell lymphoma
layoffs
Flag link:
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
JNJ
Janssen
Multiple Myeloma
CAR-T
cilta-cel
FDA
Bristol-Myers Squibb
ide-cel
Flag link:
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Fierce Biotech
ASH2020
Allogene
CAR-T
Flag link:
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
BioSpace
Bayer
CAR-T
cell therapy
Atara
Flag link:
FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial
FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial
Endpoints
Cellectis
FDA
patient deaths
CAR-T
clinical trials
Multiple Myeloma
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
CRISPR stock slides as CAR-T death overshadows signs of efficacy
CRISPR stock slides as CAR-T death overshadows signs of efficacy
Fierce Biotech
CRISPR
CRISPR Therapeutics
CAR-T
patient deaths
Flag link:
EdiGene raises $67M to take gene-editing therapies into humans
EdiGene raises $67M to take gene-editing therapies into humans
Fierce Biotech
EdiGene
gene editing
CAR-T
beta thalassemia
ET-01
ET-02
Flag link:
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Fierce Biotech
Poseida Therapeutics
solid tumors
CAR-T
SEC
prostate cancer
Flag link:
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Juno joint venture seeks IPO haul to bring CAR-Ts to China
Fierce Biotech
JW Therapeutics
Juno Therapeutics
WuXi AppTech
IPOs
Hong Kong
CAR-T
Flag link:
Novartis says CAR-T cancer therapy works in second lymphoma type
Novartis says CAR-T cancer therapy works in second lymphoma type
BioPharma Dive
Novartis
Kymriah
follicular lymphoma
CAR-T
Flag link:
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Flag link:

Pages